Auspex Pharmaceuticals Receives Loan from Square 1 Bank

Auspex Pharmaceuticals, a San Diego-based clinical stage biotechnology company, received a a term loan of undisclosed amount from Square 1 Bank.

The company intends to use the capital to supplement working capital while entering Phase 3 clinical trials for its leading compound SD-809.

Founded in 2001 and led by executive chairman Pratik Shah, Auspex Pharmaceuticals is developing compounds that integrate the properties of deuterium, a non-radioactive isotope of Hydrogen, into previously approved drugs to reduce dosage by increasing the half-life. SD-809, the company’s leading compound, aims to improve on the treatment of hyperkinetic movement disorders such as Huntington’s disease with their deuterium-substituted analogue of tetrabenazine, a commonly used drug for such disorders.



Join the discussion